Switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) in the management of wet age-related macular degeneration, reallife one year data
Archives of Clinical and Experimental Ophthalmology · 2023
DOI: 10.46439/ophthalmology.5.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical and Experimental Ophthalmology, 2023. Verfasst von Libor Hejsek und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hejsek, L., Rubesova, M., & Havlickova, L. (2023). Switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) in the management of wet age-related macular degeneration, reallife one year data. Archives of Clinical and Experimental Ophthalmology. https://doi.org/10.46439/ophthalmology.5.032
Vancouver
Hejsek L, Rubesova M, Havlickova L. Switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) in the management of wet age-related macular degeneration, reallife one year data. Archives of Clinical and Experimental Ophthalmology. 2023. doi:10.46439/ophthalmology.5.032
BibTeX
@article{Hejsek2023,
author = {Hejsek, Libor and Rubesova, Martina and Havlickova, Lenka},
title = {Switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) in the management of wet age-related macular degeneration, reallife one year data},
journal = {Archives of Clinical and Experimental Ophthalmology},
year = {2023},
doi = {10.46439/ophthalmology.5.032}
}
EUVIMED